The chief executive officer of Abintus Bio discussed the company’s in vivo approach and how it could help expand patient access to cell therapies.
Nick Boyle, PhD
Advertisement
Articles by Nick Boyle, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
Steven W. Pipe, MD, on Integrating Gene Therapy into Clinical Care for Hemophilia B
2
FDA Hits Atara Biotherapeutics’ T-Cell Immunotherapy Tabelecleucel for EBV+ PTLD With Second CRL
3
Brian Lin, PhD, on Using Genetics, Biomarkers, and Clinical Trial Readiness to Enhance ALS Care
4
Data Roundup: December 2025 Features Updates from ASH and CTAD
5